Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

AstraZeneca

Status: Completed

Conditions: Advanced Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00871585

NIS-OHR-CAS-2008/1

Details and patient eligibility

About

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.

Enrollment: 340 patients

Sex: Male

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosis of advanced prostate cancer
• Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks
• Patients capable of signing ICF

Exclusion criteria

• Patients with hypersensitivity to bicalutamide
• Patients on therapy with terfenadin, astemizol or cisapride
• Participation in a clinical study during the last 30 days